Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

In this study, we evaluated the anti-leukemia effects of concomitant BCL-2 and MAPK blockade by venetoclax in combination with MEK1/2 inhibitor GDC-0973 (cobimetinib).

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Lina Han, Qi Zhang, Ce Shi, Antonio Cavazos, Vivian R. Ruvolo, Joel D. Leverson, Monique Dail, Darren C. Phillips, Jun Chen, Sha S. Jin, Rodrigo Jacamo, Naval Daver, Elias Jabbour, Hagop M. Kantarjian, Michael Andreeff, Deepak Sampath, Marina Konopleva Source Type: research